Immunome Income Statement (2023-2025) | IMNM

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 2.36M4.26M3.56M3.83M1.03M2.36M2.91M2.74M2.93M4.01M
Operating items
Research & Development 3.91M5.72M3.82M9.64M15.37M29.08M37.20M47.89M36.87M40.45M49.19M
Selling, General & Administrative 2.92M4.32M4.38M8.04M6.00M6.98M9.53M10.45M10.69M10.04M10.95M
Other Operating Expenses 80.80M111.95M6.31M6.71M27.37M
Operating Expenses 6.83M10.04M8.20M98.48M133.33M42.37M53.43M85.71M47.56M50.49M60.14M
Operating Income -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
EBIT -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Net income details
EBT -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Profit After Tax -4.27M-5.56M-4.34M-92.63M-129.49M-36.12M-47.10M-80.25M-41.64M-43.40M-57.46M
Income from Continuing Operations -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Consolidated Net Income -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Income towards Parent Company -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Net Income towards Common Stockholders -4.47M-5.77M-4.34M-92.63M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M
Additional items
EPS (Basic) -0.35-0.46-0.36-4.22-2.51-0.60-0.78-1.28-0.52-0.50-0.65
EPS (Weighted Average and Diluted) -0.35-0.46-0.36-4.22-2.51-0.60-0.78-1.28-0.52-0.50-0.65
Shares Outstanding (Weighted Average) 12.22M12.22M12.20M42.73M59.69M59.97M60.05M62.42M86.95M87.01M87.05M
Shares Outstanding (Diluted Average) 12.18M12.20M12.20M19.84M51.54M59.94M60.21M58.64M79.41M87.01M87.96M
EBITDA -4.47M-5.77M-4.63M-94.65M-132.30M-40.01M-50.52M-82.97M-44.64M-46.48M-60.14M